Management of insomnia in sleep disordered breathing by Janssen, Hennie CJP et al.
Management of insomnia in sleep
disordered breathing
Hennie C.J.P. Janssen1, Lisette N. Venekamp1, Geert A.M. Peeters1,
Angelique Pijpers1 and Dirk A.A. Pevernagie1,2
Affiliations: 1Sleep Medicine Center Kempenhaeghe, Heeze, The Netherlands. 2Dept of Internal Medicine and
Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Correspondence: D.A.A. Pevernagie, Dept of Internal Medicine and Paediatrics, Ghent University, Corneel
Heymanslaan 10, Ghent, 9000, Belgium. E-mail: pevernagied@kempenhaeghe.nl
@ERSpublications
Obstructive sleep apnoea and insomnia frequently co-occur. Their pathophysiological relationship is
intricate, and the resulting clinical condition may be difficult to treat. Insomnia treatment can be
started first to alleviate symptoms of disturbed sleep. http://bit.ly/2kpwtEl
Cite this article as: Janssen HCJP, Venekamp LN, Peeters GAM, et al. Management of insomnia in sleep
disordered breathing. Eur Respir Rev 2019; 28: 190080 [https://doi.org/10.1183/16000617.0080-2019].
ABSTRACT Both obstructive sleep apnoea (OSA) and chronic insomnia disorder are highly prevalent in
the general population. Whilst both disorders may occur together by mere coincidence, it appears that
they share clinical features and that they may aggravate each other as a result of reciprocally adverse
pathogenetic mechanisms. Comorbidity between chronic insomnia disorder and OSA is a clinically
relevant condition that may confront practitioners with serious diagnostic and therapeutic challenges.
Current data, while still scarce, advocate an integrated and multidisciplinary approach that seems superior
over the isolated treatment of each sleep disorder alone.
Introduction
Insomnia and sleep disordered breathing (SDB) are the two most frequent sleep disorders in the general
population. Because of their high prevalence, there is a substantial chance of coincidence. When they
occur together, implications for therapeutic management may arise. It is not clear whether these disorders
should be treated separately according to prevailing standards, or whether a different, more integrated,
approach should be preferred. While insomnia and SDB are classified as entities with different
pathophysiologic mechanisms and clinical presentations, they share common features. This overlap may
blur the nosological distinction between the two conditions and may confound the logical principles of
their treatment. In this review, we expand on the semantic definitions of insomnia and SDB. We examine
their co-occurrence, potential reciprocal influence and provide clues for treatment of the combined clinical
condition.
Definitions
The fundament of insomnia is a predominant complaint of dissatisfaction with either duration or quality
of sleep in combination with daytime impairments. Operational descriptions for this clinical picture have
been provided by different scientific organisations and have gradually been adapted over time. The
International Classification of Sleep Disorders (ICSD) published by the American Academy of Sleep
Medicine (AASM) is frequently cited in the literature. The latest edition (ICSD-3) differs from the
previous ones in that the discrimination between various subtypes of insomnia has been abandoned and
“insomnia” is being defined as a disorder in its own right, irrespective of cause or comorbidities [1].
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Furthermore, a distinction is being made between chronic insomnia disorder, short-term insomnia
disorder and other insomnia disorders. The scope of this review is limited to the discussion of chronic
insomnia disorder, which is basically defined as a complaint of persistent sleep difficulty that is present
despite adequate opportunities for sleep and that results in impaired daytime functioning [1]. Chronicity is
denoted by the presence of symptoms occurring at least three times per week and persisting for at least
3 months. According to ICSD-3, the sleep/wake difficulty in insomnia should not be better explained by
another sleep disorder. It should be kept in mind that various definitions of insomnia have been applied
in the publications cited in this article. The lack of standardisation in this domain hampers the
comparison of research results.
SDB is a collective name for obstructive sleep apnoea (OSA), central sleep apnoea and sleep-related
hypoventilation syndromes. The present review deals mainly with OSA. The definition of this disorder has
also been subject to substantial changes over time, favouring the apnoea/hypopnoea index (AHI) as the
primary predictor or exposure variable for the clinical relevance of the disorder. According to the AASM,
as published in the ICSD-3, OSA is characterised by three main diagnostic features [2]: 1) the presence of
daytime and/or nocturnal symptoms including insomnia; 2) the presence of five or more predominantly
obstructive events per hour; or 3) the presence of 15 or more predominantly obstructive events per hour.
The ICSD-3 stipulates that 1 plus 2, or 3 alone, satisfy the diagnostic criteria of OSA. In contrast with
insomnia, it is not required to exclude other sleep disorders that would better explain the clinical picture.
This would imply that whenever five or more predominantly obstructive events per hour are demonstrated
in a sleep recording, symptoms of sleeplessness should not be classified as chronic insomnia disorder, but
rather as OSA. Such classification, however, would be very impractical for daily routine care, because
demographic research has shown that the prevalence of an elevated AHI may be extremely high in the
general population [3, 4]. All too often, genuine chronic insomnia disorder would be misclassified as OSA
when an increased AHI would be taken as the prevailing diagnostic criterion. In the past decade, the
usefulness of the AHI in establishing the diagnosis of clinically relevant OSA has been questioned.
Scepticism has been fed by the absence of a clear relationship between the AHI and symptom severity [5–7].
Furthermore, recent therapeutic trials with positive airway pressure (PAP) failed to show a robust impact
on relevant cardiovascular comorbidity in OSA patients who were enrolled based on AHI criteria [8, 9].
These observations prompt for clinical characterisation of OSA on other features than the mere value of
the AHI.
Co-occurrence of insomnia and OSA
Several publications have addressed the co-occurrence of chronic insomnia disorder and OSA. In a recent
systematic review and meta-analysis, ZHANG et al. [10] have evaluated published data on the co-occurrence
prevalence of insomnia and insomnia symptoms with OSA. A total of 37 studies were included in their
analysis. In OSA patients, high rates were found for overall prevalence of insomnia (38%), any insomnia
complaints (36%), difficulty falling asleep (18%), difficulty maintaining sleep (42%) and early morning
awakenings (21%). They also analysed the pooled prevalence rates of OSA based on different AHI criteria
TABLE 1 Interrelation between symptoms and clinical features associated with obstructive
sleep apnoea (OSA) and insomnia
OSA Both Insomnia
Snoring
Breathing pauses
Breath holding, gasping, choking
Frequent arousals due to sleep
disordered breathing events
Frequent awakenings
Difficulty falling asleep
Unrefreshing sleep
Fatigue
Daytime sleepiness
Attention, concentration and
memory impairment
Social and occupational
dysfunction
Mood disturbances
Reduced motivation and energy
Accidents
Worry about sleep
Decreased quality of life
Increased arousal
Excessive focus on and high
anxiety about sleep
Learned sleep-preventing
associations
Reproduced from [11] with permission.
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in patients with insomnia. The rates were 35% (AHI ⩾5 events·h−1) and 29% (AHI ⩾15 events·h−1),
respectively. These findings would suggest that OSA and insomnia mutually overlap in approximately a
third of cases.
OSA and insomnia are dissimilar from a clinical and pathophysiological point of view. From a clinical
perspective, these disorders can be modelled as orthogonal conditions, because insomnia is associated with
increased arousal and alertness, whereas in OSA excessive daytime sleepiness is the most characteristic
feature. Nevertheless, there is a substantial similarity between these two conditions regarding the nature of
clinical manifestations. In a review of seven relevant studies, LUYSTER et al. [11] have reported on
symptoms of OSA and insomnia, based on the ICSD. They found that only a minority of clinical
characteristics are distinct, whereas most daytime and night-time complaints are shared by both disorders
(table 1). They concluded that because of the substantial overlap in symptoms between insomnia and OSA
the evaluation and treatment of either condition may be compromised and that multidisciplinary
collaboration among sleep specialists is necessary. In this early review it was suggested that combination
therapy, including both cognitive behavioural therapy (CBT) for insomnia and OSA treatment, resulted in
greater improvements than either treatment strategy alone.
Insomnia profile in OSA cluster analysis
Recent research has focused on symptom scores and comorbidities of OSA to explore whether
phenotypical subtypes exist among patients with this disorder. In an Icelandic sample of 822 newly
diagnosed OSA patients with an AHI ⩾15 events·h−1, three distinct clinical clusters were identified among
which a disturbed sleep group represented 32.7% of the total cohort [12]. This cluster did not differ from
the other two clusters (i.e. the minimally symptomatic group and the group with excessive daytime
sleepiness) with respect to sex, body mass index or AHI. In a large international cohort of OSA patients,
the existence of these clusters was confirmed and complemented with two other clusters. The disturbed
sleep cluster comprised 19% of patients, with the highest rates of difficulty falling asleep (82.4%), difficulty
maintaining sleep (97.2%), waking too early (77.3%) and restless sleep (79.7%). This cluster also had the
highest rates of restless leg syndrome, hypertension, diabetes and cardiovascular disease compared to the
other clusters (minimal symptoms, upper airway symptoms with sleepiness, upper airway symptoms
dominant and sleepiness dominant) [13]. The higher frequency of essential hypertension and
cerebrovascular disease in OSA patients with insomnia complaints compared to OSA patients without
insomnia complaints was also found in a large retrospective study [14].
These cluster analyses evoke the existence of distinct clinical phenotypes among the large and ever
expanding OSA patient population. One of these phenotypes is clearly disturbed sleep showing
characteristics of chronic insomnia disorder. It remains to be determined if this trait represents a treatable
characteristic of OSA or signifies an unrelated condition that would require non-respiratory therapeutic
interventions.
The relationship between OSA and insomnia
It proves difficult to tease out causal relationships between OSA and insomnia in individual patients. Both
conditions may be unrelated, could be a clinical trait of one another, or could even negatively affect each
other. Often, empirical treatment is needed to clarify causality, as differential therapeutic responses may
point out whether the OSA condition is primary or subordinate to the insomnia component and vice versa.
OSA as a cause of insomnia
Repeated obstructive respiratory events may be instrumental to the development of sleeplessness in some
OSA patients. Several mechanisms are believed to play a role [15]. Apnoeas are invariably associated with
cortical arousals from sleep. These short interruptions of sleep may be perceived as awakenings or
continued wakefulness if they are vigorous and occur repeatedly. Nocturia is a frequent complication of
OSA. Patients have to get out of bed several times, and this mere fact is an obvious cause of sleep
disruption. Some patients expand the time in bed to compensate for not being refreshed upon awakening.
They may take periods of rest during the daytime and increase caffeine intake. These behavioural patterns
are also typical of psychophysiological insomnia, meaning that measures to alleviate daytime somnolence
may be conducive to developing problems with initiation and maintenance of sleep. Finally,
apnoea-induced arousals that are associated with sensations of breathlessness may promote anxiety, which
in turn may prime cognitive processes towards increased alertness.
If disturbed breathing is indeed the cause of insomnia, OSA targeted treatment will improve insomnia
complaints. Restoration of sleep initiation and continuity under PAP treatment has been shown in several
studies. GLIDEWELL et al. [16] studied 68 OSA patients, 53 of whom had pre-treatment insomnia symptoms.
In this group, PAP therapy reduced insomnia severity scores from moderate/severe to no/mild symptoms
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in 45% (24 out of 53 subjects). Nevertheless, more than half of the patients had persistent insomnia that
was not responsive to PAP therapy. In another trial, the effect of PAP treatment was evaluated in a large
OSA cohort that was stratified according to phenotype [17]. In the disturbed sleep group, PAP users and
non-users generally reported similar changes in insomnia symptoms after 2 years, indicating that factors
other than PAP treatment effects may play a role in the modulation of insomnia complaints. Furthermore,
differences in the type of insomnia seemed to influence the results. The disturbed sleep characteristic was
further subdivided into difficulty falling asleep (initial insomnia), waking up often during the night
(middle insomnia) and waking up early in the morning being unable to fall back asleep (late insomnia).
Improvement of middle insomnia at 2 years follow-up of PAP treatment was much more likely to occur
among patients who were adherent to PAP treatment as compared to noncompliant individuals. In
contrast, symptoms of initial and late insomnia were more likely to persist and seemed resistant to PAP
use. In another study, it was shown that PAP treatment may worsen insomnia, particularly in the initial
and late insomnia subgroups [18]. In conclusion, symptoms of insomnia may be PAP responsive in
certain patients. However, this effect is hard to predict and remains a post hoc finding in patients who are
sufficiently compliant to PAP treatment.
Insomnia as a cause of OSA
In addition to the well-known anatomical predisposition to OSA, non-anatomical factors play a substantial
role in the pathophysiology of OSA in more than half of the subjects [19] and the relative contribution of
each of them can vary markedly among OSA patients [20]. These non-anatomical features include low
pharyngeal muscle responsiveness, oversensitive ventilatory control and a low respiratory arousal threshold
during sleep. The latter trait was found to be prominent in about 37% of the cases. Patients with a low
arousal threshold awaken prematurely in response to the increased respiratory resistance that occurs
during upper airway narrowing. This pathophysiological feature may act in two ways, either as a
mechanism causing insomnia in OSA (as described above), but also as a condition that predisposes to
SDB in insomnia. Frequent awakenings and subsequent transitions to sleep invariably invoke withdrawal
of the wakefulness stimulus, which causes breathing instability and predisposes to upper airway
obstruction. This effect may be greater in OSA patients than in healthy subjects [21]. Circumstantial
evidence from clinical practice supports this interaction (personal observations). Not infrequently, a
temporary increase in AHI can be observed on the readout of PAP devices in OSA patients who are
otherwise well-controlled with PAP therapy, but who suffer from transient bouts of insomnia (figure 1).
Moreover, treatment with hypnotics has been shown to reduce OSA severity in OSA patient subgroups
with a low respiratory arousal threshold. ECKERT and co-workers [22, 23] have successfully used
eszopiclone and trazodone in OSA patients to increase the arousal threshold and to lower the AHI. These
effects, being modest on average, confirm the multifactorial nature of OSA. It is intriguing to hypothesise
that factors such as high loop gain and low arousal threshold might be related to clinical conditions such
as stress and anxiety, which are often implicated in the perpetuation of chronic insomnia disorder. This
hypothesis, however, remains to be proven.
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FIGURE 1 Temporary insomnia-induced increases of apnoea–hypopnea index (AHI) under continuous positive
airway pressure (CPAP) therapy. In a 75-year-old male patient diagnosed with obstructive sleep apnoea (AHI
65 events·h−1), CPAP administered at a level of 8 cmH2O was effective at controlling the AHI. He experienced
two episodes of insomnia as a result of temporary marital disharmony. During these incidents AHI increased
dramatically, although CPAP settings and use of drugs or alcohol remained unchanged. When normal sleep
resumed the AHI fell back to baseline levels.
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Is there a reciprocal influence between insomnia and sleep apnoea?
A mutual reinforcement of negative effects (“positive feedback loop”) may occur when OSA and insomnia
are both present (figure 2). In this instance, the above-mentioned causal relationships are bidirectional in
nature. The acronym “COMISA” has been coined by some authors to denote the intricate connection
between both pathological entities and to point out that the clinical presentation of the comorbid
condition may actually be worse than expected from the single contribution of each individual component
[14, 15, 24]. In line with this hypothesis stands the observation that some patients with COMISA
experience more severe sleep disturbance than patients with either disorder alone [25]. In COMISA
patients, daytime symptom scores tend to be higher and rates of psychiatric and cardiovascular
comorbidities are reportedly more frequent [15].
Another common finding is that COMISA is more difficult to treat than either OSA or insomnia alone.
Reduced compliance to PAP therapy is frequently observed. EYSTEINSDOTTIR et al. [26] followed 796 OSA
patients (AHI ⩾15 events·h−1) after commencement of PAP treatment over a mean period of 7 years. It
was shown that having initial or late insomnia complaints at the start was associated with quitting PAP
treatment early among non-obese patients. Similar findings came out of a French cohort of OSA patients
with a mean initial AHI of 34.6±20.7 events·h−1 [27]. It appeared that sleep onset and sleep maintenance
insomnia were inversely related to PAP compliance. Inducing or worsening insomnia complaints is a
frequent cause of noncompliance to PAP therapy [11]. Similarly, treatment of insomnia with hypnotics
may worsen SDB. In a recent retrospective case–control study, evidence was found that the use of
benzodiazepines might increase the risk of acute respiratory failure in OSA patients [28].
Eventually, one should realise that, given the high prevalence of both insomnia and OSA, the
co-occurrence of both conditions can be due to mere coincidence in any given patient. On the one hand,
both may be significant to the constellation of complaints (and thus warrant treatment), and on the other
hand, either one could be of less importance, or even be irrelevant. Reduced total sleep time or sleep
efficiency in the absence of daytime symptoms should not be labelled as insomnia [1]. An increased AHI,
even in the presence of daytime symptoms, does not necessarily qualify as clinically relevant OSA [29].
Proficient clinical judgement is paramount in the proper assessment of this complex problem.
Methodological issues
Appraisal of the literature on the co-existence of insomnia and OSA confronts the reader with several
methodological issues. The formulation of a working hypothesis on the complex interaction between these
two entities is likewise hampered by conceptual limitations. In recent systematic reviews, available studies
were compared with respect to prevalence of co-occurrence of insomnia and OSA [10] and treatment of
comorbid insomnia and OSA [24]. Both studies draw attention to the limited number of high-quality
publications and to the inconsistency of the methodology. Demographic inclusion criteria vary highly
among studies. Different definitions and cut-off values of markers for clinical severity are used for both
Psycho-physiological
mechanisms
Bio-physiological
mechanisms
Positive feedback loop
Sleep disordered breathing
Sleep disruption insomnia
FIGURE 2 Potential pathophysiological feedback mechanism of COMISA. This scheme represents the potential
positive feedback loop between sleep disordered breathing (obstructive sleep apnoea) and sleep disruption
(insomnia), explaining why the resultant clinical picture may be worse than what can be expected from the
contribution of either component alone. Moreover, as a result of this vicious circle, interventions geared to
treat either insomnia or obstructive sleep apnoea may have adverse effects to the comorbid component
(e.g. sleep restriction therapy may aggravate somnolence in obstructive sleep apnoea and continuous positive
airway pressure therapy may worsen insomnia).
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insomnia and OSA. Definitions on adherence to treatment are also disparate. Moreover, studies are
coloured by the different disciplines, where pulmonologists and sleep physicians tend to put emphasis on
apnoeic events, whereas psychologists focus more on insomnia features. One study concluded that the
contemporary level of evidence is not yet sufficient for a meta-analysis on COMISA therapy [24]. It is a
challenge for future research to standardise definitions and methods in order to come up with comparable
research results.
Clues for clinical management
Assessment of combined insomnia with OSA
If an evaluation of insomnia/OSA is warranted, an efficient diagnostic procedure is mandatory [30]. The
diagnosis of insomnia is founded on comprehensive assessment of several clinical aspects and includes
proficient history taking, the recording of sleep diaries and physical examination. Complementary
techniques such as actigraphy may be indicated in certain cases [31].
Polysomnography, which is not routinely recommended for the assessment of insomnia [31], is carried
out in patients with suspected OSA to quantify the obstructive breathing events. Polysomnography will
clearly show the insomnia-related disturbances of sleep initiation and sleep maintenance in the
hypnogram. Polygraphy does not include recording of neurophysiological variables and is intrinsically
ill-suited to document the characteristics of insomnia. Moreover, the AHI will be underestimated with
polygraphy because wakefulness and arousals go unnoticed.
Empirical therapeutic approach
Given the fact that medical evidence is actually lacking, no formal recommendations or guidelines on
treatment of insomnia/OSA can be made. Treatment of this composite condition relies on clinical
judgement and implies the mastering of pertinent knowledge and skills in the field of clinical sleep
medicine by the practitioner. Sleep physicians and sleep psychologists should be aware of their mutual
areas of interest. In light of this, the importance of an integrated, interdisciplinary approach to insomnia/
OSA must be emphasised.
Clinical judgement should guide whether to start with PAP therapy (or another suitable treatment option
for OSA) or CBT for insomnia, or both. It has been demonstrated in a retrospective trial including 455
subjects that CBT for insomnia can effectively treat insomnia in patients with comorbid OSA [32].
Significant improvements were found in insomnia symptoms, global insomnia severity, and daytime
functioning measures during and following treatment. Furthermore, improvements were not different
between patients with or without comorbid OSA. Finally, it became evident that the effectiveness of CBT
for insomnia was not impaired by the presence of OSA. The same group of investigators recently showed
that in OSA patients with comorbid insomnia, CBT for insomnia prior to initiating continuous positive
airway pressure (CPAP) treatment improves CPAP use and insomnia symptoms compared to commencing
CPAP without CBT for insomnia [33]. While these findings would benefit from replication by other
research groups, they deliver support to the contention that patients with comorbid insomnia and OSA can
be safely and effectively treated with CBT for insomnia prior to or together with the start of OSA therapy.
Conclusions
Current literature indicates that OSA and insomnia frequently co-occur. The interaction between these two
conditions may be variable and range from insignificant to mutually detrimental as a result of a positive
feedback loop. Insight into these presumed interactions is hampered by semantic issues, such as the lack of
universally accepted operational definitions of insomnia and OSA. The co-incidence of insomnia with OSA is a
condition that is often puzzling to practitioners. Recent evidence suggests that CBT for insomnia may be
started as first-line treatment for this comorbid disorder. Following alleviation of insomnia symptoms,
treatment of OSA may ensue. The intricacies of combined OSA/insomnia warrant management by
practitioners trained in clinical sleep medicine in the context of an integrated and multidisciplinary care setting.
Conflict of interest: None declared.
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